Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its price target reduced by investment analysts at BMO Capital Markets from $491.00 to $479.00 in a research note issued to investors on Thursday. The firm presently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective indicates a potential upside of 18.41% from the company’s current price.
Other equities analysts have also recently issued research reports about the company. Bank of America Corporation reissued a “buy” rating and set a $593.00 price objective (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Barclays PLC reaffirmed an “equal weight” rating and set a $450.00 price objective (up previously from $400.00) on shares of Regeneron Pharmaceuticals in a report on Saturday, July 22nd. Canaccord Genuity set a $522.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, July 28th. Credit Suisse Group downgraded Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price target on the stock. in a research note on Friday, July 14th. Finally, Citigroup Inc. restated a “buy” rating and issued a $575.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 7th. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $481.49.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $1.67 on Thursday, hitting $404.54. The stock had a trading volume of 771,100 shares, compared to its average volume of 900,360. Regeneron Pharmaceuticals has a 12 month low of $340.09 and a 12 month high of $543.55. The company has a quick ratio of 3.21, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The company has a market cap of $43,525.81, a P/E ratio of 35.17, a PEG ratio of 1.40 and a beta of 1.56.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period in the previous year, the firm posted $3.13 EPS. research analysts expect that Regeneron Pharmaceuticals will post 13.77 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) PT Lowered to $479.00” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/11/regeneron-pharmaceuticals-inc-regn-pt-lowered-to-479-00.html.
In other news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Robert E. Landry sold 468 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $476.45, for a total value of $222,978.60. Following the sale, the senior vice president now owns 9,099 shares in the company, valued at $4,335,218.55. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,942 shares of company stock worth $42,064,076. Company insiders own 10.80% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Fieldpoint Private Securities LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $130,000. Sterling Investment Advisors Ltd. lifted its stake in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares during the last quarter. FNY Partners Fund LP lifted its stake in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 200 shares during the last quarter. Alpha Windward LLC raised its position in shares of Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 1 shares in the last quarter. Finally, IFP Advisors Inc raised its position in shares of Regeneron Pharmaceuticals by 33.2% in the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 96 shares in the last quarter. 67.63% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.